Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies

被引：1

作者：

de Groot, Fleur A. ^{[1
]}

Dekker, Tim J. A. ^{[2
]}

Doorduijn, Jeanette K. ^{[3
]}

Bohringer, Stefan ^{[5
,34
]}

Brink, Mirian ^{[4
]}

de Groen, Ruben A. L. ^{[1
]}

de Haan, Lorraine M. ^{[6
]}

Woei-A-Jin, F. J. Sherida H. ^{[7
]}

Noordenbos, Troy ^{[6
]}

Sijs-Szabo, Aniko ^{[1
]}

Oudshoorn, Mirjam A. ^{[1
]}

Lam, King H. ^{[8
]}

Diepstra, Arjan ^{[9
]}

te Boome, Liane C. J. ^{[10
]}

Terpstra, Valeska ^{[11
]}

Bohmer, Lara H. ^{[12
]}

Nicolae, Alina ^{[13
]}

Posthuma, Eduardus F. M. ^{[14
]}

Koens, Lianne

Durian, Marc F. ^{[15
,16
]}

Stavast, Jeroen ^{[17
]}

van der Poel, Marjolein W. M. ^{[18
]}

Hamid, Myrurgia Abdul ^{[19
]}

Stevens, Wendy B. C. ^{[20
]}

van Rooij, Sjo L. M. ^{[21
]}

Oostvogels, Rimke S. ^{[22
]}

Muhlebner, Angelika ^{[23
]}

Neelis, Karen J. ^{[24
]}

van den Brand, Michiel ^{[25
]}

Tousseyn, Thomas ^{[26
]}

Dierickx, Daan ^{[27
]}

de Weerdt, Okke ^{[28
]}

Beeker, Aart ^{[29
]}

Jansen, Patty M. ^{[6
]}

Kersten, Marie Jose ^{[30
,31
]}

Zijlstra, Josee M. ^{[30
,31
]}

Chamuleau, Martine E. D. ^{[30
,31
]}

Veelken, Hendrik ^{[1
]}

Bromberg, Jacoline C. E. ^{[32
]}

Nijland, Marcel ^{[33
]}

Vermaat, Joost S. P. ^{[1
]}

机构：

[1] Leiden Univ, Dept Hematol, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands

[2] Leiden Univ, Med Ctr, Dept Internal Med, Leiden, Netherlands

[3] Univ Med Ctr Rotterdam, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[4] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, Utrecht, Netherlands

[5] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands

[6] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands

[7] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium

[8] Erasmus MC, Dept Pathol, Rotterdam, Netherlands

[9] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands

[10] Haaglanden Med Ctr, Dept Hematol, The Hague, Netherlands

[11] Haaglanden Med Ctr, Dept Pathol, The Hague, Netherlands

[12] Haga Teaching Hosp, Dept Biostat, The Hague, Netherlands

[13] Haga Teaching Hosp, Dept Neurol, The Hague, Netherlands

[14] Reinier de Graaf Gasthuis, Dept Internal Med, Delt, Netherlands

[15] Univ Amsterdam, Amsterdam Univ Med Ctr, Med Ctr, Amsterdam, Netherlands

[16] Elisabeth TweeSteden Ziekenhuis Tilburg, Dept Hematol, Tilburg, Netherlands

[17] Elisabeth TweeSteden Ziekenhuis Tilburg, Dept Pathol, Tilburg, Netherlands

[18] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Internal Med, Div Hematol,Med Ctr, Maastricht, Netherlands

[19] Maastricht Univ, Dept Pathol, Med Ctr, Maastricht, Netherlands

[20] Radboud Univ Nijmegen, Dept Hematol, Med Ctr, Nijmegen, Netherlands

[21] Univ Med Ctr Utrecht, Dept Neurol, Utrecht, Netherlands

[22] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands

[23] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands

[24] Leiden Univ, Med Ctr, Dept Radiotherapy, Leiden, Netherlands

[25] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, Nijmegen, Netherlands

[26] Univ Hosp Leuven, Dept Pathol, Leuven, Belgium

[27] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium

[28] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands

[29] Spaarne Gasthuis, Dept Internal Med, Haarlem, Netherlands

[30] Univ Amsterdam, Dept Hematol, Canc Ctr Amsterdam, Med Ctr, Amsterdam, Netherlands

[31] LYMMCARE, Amsterdam, Netherlands

[32] Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands

[33] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[34] Leiden Univ, Med Ctr, Med Ctr, Leiden, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 213卷

关键词：

PCNSL; Clinical characteristics; Survival outcomes; High-dose methotrexate; Induction; Polychemotherapy; Consolidation; PRIMARY CNS LYMPHOMA; INTERNATIONAL EXTRANODAL LYMPHOMA; HEALTH-ORGANIZATION CLASSIFICATION; STEM-CELL TRANSPLANTATION; CHEMOTHERAPY; RADIOTHERAPY; CHEMOIMMUNOTHERAPY; RANDOMIZATION; RITUXIMAB;

D O I：

10.1016/j.ejca.2024.115068

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Given the rarity of primary central nervous system lymphoma (PCNSL), evaluations of different high-dose methotrexate-(HD-MTX)-based treatment regimens is sparse. This retrospective, multicenter study evaluates clinical characteristics and outcomes (progression-free, overall and disease-specific survival) after five HD-MTX-based polychemotherapeutic regimens and two consolidation therapies. 346 patients with histologically confirmed PCNSL, treated with >= 1 cycle HD-MTX-based strategies (>= 3g/m(2)/cycle) were included. The regimens included MATRIX (HD-MTX, HD-AraC, thiotepa, and rituximab), (R)MBVP +/- HD-AraC (HD-MTX, teniposide/etoposide, carmustine, prednisolone, +/- HD-AraC, +/- rituximab), (R)MP (HD-MTX, procarbazine, +/- rituximab), and a combination of HD-MTX and HD-AraC. The overall response rate after induction was 69 %, 28 % complete remission and progressive disease was observed in 100 (29 %) patients. 126 (36 %) patients received consolidation, including high-dose-BCNU-thiotepa with autologous stem cell transplantation (HD-BCNU-TT/ASCT, n = 59 (17 %)) or whole brain radiotherapy (WBRT, n = 67 (19 %)). Clinical characteristics associated with adverse mortality risk by multivariable prognostication contained age > 60 years (HR 1.61, p = 0.011), elevated LDH (HR 1.75, p = 0.004) and WHO status >= 2 (HR 1.56, p = 0.010). Independently, induction regimens containing HD-AraC demonstrated survival benefit compared to induction regimens without HD-AraC (HR 0.59, p = 0.002). Without preference for HD-BCNU-TT/ASCT or WBRT, a favorable effect of consolidation (HR 0.44 and HR 0.42, p < 0.001) was confirmed, also with consolidation as time-dependent variable. Competing risk analysis showed similar low incidence of lymphoma-unrelated deaths in consolidated and unconsolidated patients. This study confirms that age, elevated LDH and WHO status increase the mortality risk. HD-AraC containing treatment regimens and consolidation with HD-BCU-TT/ASCT or WBRT were associated with superior survival, including a favorable low incidence of lymphoma-unrelated deaths.

引用

页数：9

共 50 条

[21] Early Urinary Potassium Level Predicts High-dose Methotrexate Elimination Delay in Primary Central Nervous System Lymphoma
Harlay, Vincent
Bertucci, Alexandre
Boucard, Celine
Petrirena, Gregorio
Campello, Chantal
Barrie, Maryline
Autran, Didier
Chinot, Olivier
Tabouret, Emeline
ANTICANCER RESEARCH, 2024, 44 (10) : 4427 - 4433
[22] White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab
Fayez Estephan
Xiaobu Ye
Omar Dzaye
Nina Wagner-Johnston
Lode Swinnen
Douglas E. Gladstone
Rich Ambinder
David Olayinka Kamson
Sebastian Lambrecht
Stuart A. Grossman
Doris D. M. Lin
Matthias Holdhoff
Journal of Neuro-Oncology, 2019, 145 : 461 - 466
[23] Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China
Sun, Xuefei
Wu, Yuchen
Xing, Ruixian
Bai, Xueyan
Qian, Jun
Zhu, Hong
Cui, Qu
Chen, Yuedan
Liu, Qing
Lai, Wenyuan
Li, Junhong
Wang, Yaming
Sun, Shengjun
Gao, Chunji
Ji, Nan
Liu, Yuanbo
FRONTIERS IN ONCOLOGY, 2022, 12
[24] What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?
Dalia, Samir
Price, Samantha
Forsyth, Peter
Sokol, Lubomir
Jaglal, Michael
LEUKEMIA & LYMPHOMA, 2015, 56 (02) : 500 - 502
[25] Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy
Sasaki, Nobuyoshi
Kobayashi, Keiichi
Saito, Kuniaki
Shimizu, Saki
Suzuki, Kaori
Lee, Jeunghun
Yamagishi, Yuki
Shibahara, Junji
Takayama, Nobuyuki
Shiokawa, Yoshiaki
Nagane, Motoo
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (09) : 999 - 1008
[26] Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment
Zhou, Liying
Li, Qing
Xu, Jingshen
Wang, Shuaikang
Song, Zhiqiang
Chen, Xinyi
Ma, Yan
Lin, Zhiguang
Chen, Bobin
Huang, He
NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
[27] Treatment of Primary Central Nervous System Lymphoma with High-dose Methotrexate and Radiotherapy in HIV-negative Patients
Jalaeikhoo, Hasan
Yekaninejad, Mir Saeed
Hajizamani, Saeideh
Rahim, Fakher
Ahmedzadesh, Ahmed
Keyhani, Manoutchehr
Hariri, Behrooz Sadeghi
Saki, Najmaldin
ARCHIVES OF IRANIAN MEDICINE, 2015, 18 (09) : 577 - 581
[28] Patient Reported and Clinical Outcomes after High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma
Beer, Sina A.
Wirths, Stefan
Vogel, Wichard
Tabatabai, Ghazaleh
Ernemann, Ulrike
Merle, David A.
Bethge, Wolfgang
Moehle, Robert
Lengerke, Claudia
CANCERS, 2023, 15 (03)
[29] High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience
Yoon, Wan-Soo
Park, Jae-Sung
Kim, Young-il
Chung, Dong-Sup
Jeun, Sin-Soo
Hong, Yong-Kil
Yang, Seung Ho
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (01) : 123 - 130
[30] High-dose methotrexate combined with rituximab improves the survival rate of patients with primary central nervous system lymphoma
Ma, Jing
Ma, Xianjun
JOURNAL OF BUON, 2021, 26 (02): : 366 - 372

← 1 2 3 4 5 →